North American pharmacy is one of those industries that looks deceptively simple from the outside: a counter, prescriptions, a few aisles of consumer goods, and a familiar logo on the corner. But financially, it is a multi-layered system of spread economics, contract timing, regulatory shockwaves, and scale advantages—where “volume up” can still coexist with “profit down.”
Today’s CVS reporting is useful precisely because CVS sits at the center of the modern pharmacy stack: retail dispensing, a major PBM (Caremark), specialty pharmacy capabilities, and an insurance arm (Aetna). When CVS says a part of the machine is improving or deteriorating, it often signals where the broader market is headed—especially in a period of heightened scrutiny on drug pricing and PBM practices, and after years of margin compression in brick-and-mortar dispensing.
This article uses CVS’s latest results as a prism to explain the current financial situation of the North American pharmacy business, why the sector is still under pressure despite rising prescription volumes, and which strategic moves are most likely to define winners and losers through 2026–2028.
1) The CVS print: what matters (and why it matters beyond CVS)
CVS reported fourth-quarter and full-year 2025 results today. The headline tells a familiar story: revenue growth and prescription volume strength, paired with a more complicated profitability picture driven by reimbursement dynamics, mix shift, and policy changes in government programs.
Key takeaways from today’s CVS reporting
- Scale is still generating revenue momentum: CVS reported Q4 revenue of $105.7B (+8.2% YoY) and full-year revenue of $402.1B (+7.8% YoY).
- Adjusted EPS is resilient, but pressured: Q4 adjusted EPS was $1.09, reflecting that operational improvements can be partially offset by policy and mix effects.
- “Pharmacy is back” is the signal: commentary and external coverage emphasize improved performance in pharmacy-related activities and higher prescription volumes.
- Guidance discipline: CVS maintained 2026 adjusted EPS guidance ($7.00–$7.20) and reaffirmed a revenue target around $400B+, which the market interpreted as cautious.
Two reasons these points matter for the entire sector:
- CVS is the best “system integrator” proxy for North American pharmacy economics—retail dispensing, PBM contracting, specialty, and insurance risk all under one roof.
- Policy changes are now showing up in P&L line items faster than before, especially in Medicare-related programs. The distance between Washington and the pharmacy counter is shrinking.
Bottom line: CVS’s reporting supports a broader thesis: North American pharmacy is not collapsing, but it is being re-priced. That re-pricing is uneven across the value chain—and brutally visible at the retail store level.
2) The sector’s paradox: prescriptions rise, but margins don’t follow
Prescription volumes are structurally supported by demographics (aging population), chronic disease prevalence, and higher diagnosis and treatment rates. Yet retail pharmacy profitability has been persistently weak. Why?
Because dispensing has become a “low-margin fulfillment business”
The simplest way to think about retail pharmacy today is to compare it to parcel delivery:
- The unit count (scripts) can rise steadily…
- …while the reimbursement per unit declines…
- …and the labor intensity remains non-trivial…
- …making incremental volume less valuable than it appears.
Retail pharmacy used to benefit from a more balanced model: acceptable gross margin on dispensing plus high-margin front-store categories. That model has been undermined by:
- Reimbursement compression (especially in generics and preferred networks)
- PBM network steering that rewards the lowest net cost, not the retailer’s margin
- Front-store erosion (mass retail, e-commerce, and consumer trade-down)
- Higher wage expectations for pharmacists and technicians in a tight labor market
So yes: volumes can increase, but the “per-script contribution” can shrink, sometimes faster than the volume growth. That is why the industry feels like it is always “busy,” but not always “healthy.”
3) The modern pharmacy value chain: where the money is (and isn’t)
To understand the financial situation, we need to stop treating “pharmacy” as one business. It’s at least four businesses:
A) Retail dispensing (the store network)
This is the most visible part—and often the most financially stressed. It carries:
- High fixed costs (rent, staffing, shrink)
- Regulatory requirements (pharmacist coverage, controlled substances compliance)
- Limited pricing power (reimbursement dictated by plan/PBM contracts)
B) PBMs (pharmacy benefit managers)
PBMs are the economic “traffic controllers” of the system. They influence:
- Formulary placement
- Prior authorization and utilization management
- Network design (who gets volume)
- Rebate flows and admin fees
PBMs are also where political and regulatory scrutiny is intensifying, with employers and states demanding more transparency on pricing and rebate mechanics.
C) Specialty pharmacy (the profit pool magnet)
Specialty drugs are expensive, complex, and growing. Specialty pharmacy tends to offer:
- Higher revenue per patient
- More service intensity (adherence programs, cold chain, clinical support)
- Stronger strategic defensibility through payer/provider integration
But specialty economics are also contested—between PBMs, health systems, pharma manufacturers, and specialty distributors.
D) Health insurance (risk + policy exposure)
Integrated players like CVS (Aetna) and UnitedHealth (Optum + insurance) face a different reality: insurance margins can swing rapidly when medical cost trends move or when policy changes alter benefit design economics.
4) Why the retail corner store is shrinking: closures are not a “temporary cycle”
Over the past few years, store closures have shifted from isolated rationalizations to a structural redesign of the footprint.
The drivers
- Front-store economics deteriorated (lower discretionary spending, price competition, and shifting shopping behavior)
- Labor model strain (pharmacist burnout, technician shortages, higher wage pressure)
- Lower margin scripts due to network pricing and aggressive reimbursement rates
- More prescriptions moving to mail or 90-day where allowed and incentivized
There is also a geographic equity issue: closures often hit communities where the pharmacy is not “nice to have,” but a healthcare access point. That makes the sector politically sensitive, which can create regulatory friction for the chains—even as the economics push them to consolidate further.
5) CVS vs Walgreens: two different problems wearing the same uniform
The market often bundles CVS and Walgreens together because both operate large retail pharmacy networks. But their financial engines are fundamentally different.
| Dimension | CVS (integrated model) | Walgreens-style model (retail-heavy) |
|---|---|---|
| Core advantage | PBM + insurance + retail + specialty synergies | Retail scale + convenience footprint |
| Main vulnerability | Policy risk in Medicare/insurance + PBM scrutiny | Dispensing margin compression + front-store erosion |
| Strategic lever | Optimize across the stack (payer + pharmacy) | Reinvent store economics and diversify services |
| What “good news” looks like | Stabilized medical cost trend + strong pharmacy services | Improved reimbursement + higher-margin services |
CVS’s latest reporting reinforces why integration is attractive: when retail is under pressure, PBM/specialty scale can partially offset. A retail-heavy model has fewer internal shock absorbers.
6) Medicare Part D and the new reality: policy is now a margin line item
The Inflation Reduction Act (IRA) continues to reshape the Medicare drug benefit landscape. Even without diving into every provision, the practical outcome is clear for operators:
- Benefit design changes can shift costs across stakeholders (plans, pharmacies, manufacturers, patients).
- Timing effects (when costs are recognized) can distort quarter-to-quarter profitability comparisons.
- Medicare Advantage and Medicare-related businesses are facing tighter economics, which feeds back into contracting behavior.
For pharmacy, the second-order effects matter: when payer margins tighten, payers and PBMs become more aggressive in seeking savings—often pressuring retail reimbursement and intensifying utilization controls.
7) PBM scrutiny and “transparency pressure”: the center of gravity is moving
North American pharmacy economics cannot be discussed without acknowledging PBMs. The PBM value proposition is real (negotiating leverage, formulary management, utilization controls), but the model has become controversial because of perceived opacity in:
- Rebate flows
- Spread pricing
- Pharmacy reimbursement methodology
- Audit practices and network contract complexity
Two strategic trends are accelerating:
A) Employers experimenting with alternative PBM models
Large employers are increasingly testing transparent or pass-through PBM models, carve-outs, and independent audits, especially for specialty and GLP-1 spend control.
B) Government pressure at state and federal levels
Regulators are pushing for clearer reporting and fairness standards, often driven by independent pharmacy viability and patient access concerns.
If PBM economics are forced to become more transparent, the key question becomes: where does the margin go? It will not disappear; it will be redistributed among plans, pharmacies, manufacturers, and patients—depending on the exact regulatory outcomes.
8) The growth engine that changes everything: specialty + GLP-1 + chronic complexity
Specialty pharmacy is the most important growth engine in the sector—and also the biggest battleground. The forces at play:
- Specialty drug pipeline strength (oncology, immunology, rare disease)
- GLP-1 expansion (diabetes and weight management) driving both demand and payer pushback
- Adherence + outcomes focus pushing pharmacies to prove they can reduce total cost of care
Specialty economics favor scale, data, and integration. That is why CVS’s “pharmacy performance” narrative matters: it typically includes the parts of pharmacy that have strategic gravity—PBM contracting and specialty fulfillment—not only the physical store.
9) So what is the sector’s “current financial situation” in one sentence?
North American pharmacy is financially stable in aggregate revenue terms, but structurally stressed at the retail dispensing layer, with profitability increasingly migrating to integrated, data-driven, specialty-oriented models.
This is why you see, simultaneously:
- Strong top-line numbers at the largest players
- Footprint reductions and store closures
- Independent pharmacy distress in many markets
- A surge in specialty capabilities and payer controls
- Political attention on “who captures the savings”
10) The strategic playbook for 2026–2028: what operators must do
Whether you are a large chain, a regional operator, an independent pharmacy, or a healthcare-adjacent investor, the winning playbook is converging around five imperatives.
1) Treat retail as a healthcare access node, not a convenience store
If front-store retail economics continue to weaken, the store must monetize healthcare services: immunizations, point-of-care testing, chronic programs, and tightly integrated digital refill journeys. Retail square footage must justify itself with healthcare value, not only product merchandising.
2) Optimize network footprint with brutal realism
Not every store can be saved. The winning approach is to redesign the network around:
- Prescription density
- Local payer mix and reimbursement quality
- Proximity to clinics/health systems
- Labor availability
3) Master specialty execution and payer requirements
Specialty requires operational excellence (cold chain, adherence, clinical coordination) and contract sophistication (limited distribution drugs, outcomes-based models, prior auth navigation). This is where scale and data outperform brand recognition.
4) Build “trust architecture” around pricing and contracting
PBM scrutiny will not fade. Transparent reporting, auditable contract constructs, and clearer patient/employer narratives become competitive advantages—especially as employers seek alternatives.
5) Invest in automation and workflow redesign
Dispensing workflows must be industrialized: central fill, robotics, improved adjudication, better exception handling, and technician upskilling. Without workflow transformation, labor costs will keep squeezing already thin per-script contribution.
11) What to watch next (a pragmatic checklist)
- CVS guidance revisions: do they stay cautious, or do they gain confidence as pharmacy performance improves?
- Retail closure pace: how quickly do major chains rationalize footprints in 2026?
- PBM transparency moves: employer carve-outs, state actions, and any federal momentum.
- Specialty competition: payer-owned vs provider-owned vs PBM-owned specialty channels.
- GLP-1 management: utilization controls, formulary decisions, and outcomes evidence shaping access.
Conclusion: CVS’s print is not “a CVS story”—it’s a sector story
Today’s CVS reporting is best read as an updated map of North American pharmacy economics. The system is not short of demand. It is short of economic balance—because the cost of operating the last mile (retail dispensing) is rising while reimbursement is structurally constrained.
The sector’s future belongs to organizations that can do three things at once: (1) run retail with industrial efficiency, (2) win in specialty where complexity is monetizable, and (3) operate with enough transparency to survive the political cycle around PBMs and drug costs.
In other words: pharmacy is becoming less of a “store business” and more of a healthcare logistics + data + contracting business. CVS is positioned for that world—yet still exposed to the policy and insurance volatility that comes with being at the center of the system.
If you want one mental model for 2026: the pharmacy sector is not dying. It is consolidating, re-priced, and re-architected—script by script.
Olivier Delestre-Levai 